Country-by-Country Basis Sample Clauses

Country-by-Country Basis. For each Product, royalties shall be payable by a Party on a country-by-country basis solely with respect to Net Sales for any country where such Product is manufactured or sold in which there is a Valid Claim under the applicable Factor Patent Rights or Additional Factor Patent Rights. However, for sales of a Product which is manufactured in a country in which there is a Valid Claim under the applicable Factor Patent Rights or Additional Factor Patent Rights, but sold in a country where the applicable Factor Patent Rights or Additional Factor. Patent Rights do not exist, the royalties payable by the Parties for sales in that country shall be reduced by fifty percent (50%) if products are being sold in that country which directly compete with such Product.
AutoNDA by SimpleDocs
Country-by-Country Basis. For each GDF-8 Licensed Product, royalties shall be payable by a Party on a country-by-country basis solely with respect to Net Sales for any country where such GDF-8 Licensed Product is manufactured or sold in which there is a Valid Claim under the applicable GDF-8 Patent Rights. However, for sales of a GDF-8 Licensed Product which is manufactured in a country in which there is a Valid Claim under the applicable GDF-8 Patent Rights, but sold in a country where there is no existing Valid Claim under the applicable GDF-8 Patent Rights, the royalties payable hereunder by the Parties for sales in that country shall be reduced by fifty percent (50%) if products are being sold in that country which directly compete with such GDF-8 Licensed Product.

Related to Country-by-Country Basis

  • Country Specific Terms Appendix A contains additional terms and conditions of the Agreement applicable to Participants residing in those countries. In addition, Appendix A also contains information and notices of exchange control and certain other issues of which the Participant should be aware.

  • Particular Methods of Procurement of Goods and Works International Competitive Bidding. Goods and works shall be procured under contracts awarded on the basis of International Competitive Bidding.

  • Country [insert country where ITT is issued]

  • Particular Methods of Procurement of Goods Works and Services (other than Consultants’ Services)

  • Country-Specific Provisions Argentina

  • Net Sales The term “

  • Development Milestone Payments (i) In addition to the Closing Date Merger Consideration (less the Remaining Option Consideration and Rights Proceeds Amount, if any) and any Net TNF Sales Payments (as defined below), upon the attainment of the development ** Portions of the Exhibit have been omitted and have been filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. milestones set forth below (each, a “Development Milestone”), Parent shall, or shall cause the Surviving Corporation to, [**] after the occurrence of each Development Milestone, deliver to the Paying Agent (for further payment to the holders of Stock Certificates and Stock Agreements outstanding immediately prior to the Effective Time), via wire transfer of immediately available funds, the respective amounts set forth below minus, in each case, the applicable Contingent Consideration Distribution Fee associated therewith and any amount designated by the Stockholders’ Representatives to be placed in the Administrative Expense Account (each, a “Development Milestone Payment” and collectively, the “Development Milestone Payments”): (A) Upon FDA approval of Reslizumab for the treatment of eosinophilic esophagitis, a cash payment of [**]; (B) Upon marketing authorization of Reslizumab for the treatment of eosinophilic esophagitis being granted by the European Commission in accordance with Regulation (EC) No. 726/2004, a cash payment of [**]; (C) If Res 5-0010 Asthma Study Completion has not occurred on or prior to the Closing Date, then upon the occurrence of the Res 5-0010 Asthma Study Completion, a cash payment of $50,000,000 (fifty million dollars) (the “Res 5-0010 Asthma Payment”); (D) Upon FDA approval of Reslizumab for any asthma indication, a cash payment of [**]; (E) Upon marketing authorization of Reslizumab for the treatment of any asthma indication being granted by the European Commission in accordance with Regulation (EC) No. 726/2004, a cash payment of [**]; and (F) Upon FDA approval of an Oral Anti-TNF Product, a cash payment of [**].

  • CLASSIFICATIONS AND WAGE RATES A current list of Field job classifications and applicable wage rates for the Nevada Irrigation District are set forth in the District Wage Schedule.

  • Other Methods of Procurement of Goods and Works The following table specifies the methods of procurement, other than International Competitive Bidding, which may be used for goods and works. The Procurement Plan shall specify the circumstances under which such methods may be used: (a) National Competitive Bidding (b) Shopping (c) Direct Contracting

  • Royalty Term On a country-by-country and Licensed Product-by-Licensed Product basis, royalty payments in the Territory shall commence upon the first commercial sale of such Licensed Product, whether such sale is to a Public Purchaser, Governmental Authority or private entity or person and whether such sale is made under an EUA or Key Approval, in such country in the Territory and will terminate upon the later of: (a) the expiration, invalidation or abandonment date of the last Valid Claim of the Patents in the country of sale or manufacture of such Licensed Product in the Territory or (b) expiration of regulatory exclusivity of such Licensed Product in such country of sale in the Territory (the “Royalty Term”).

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!